Rhythm Pharmaceuticals

151 articles about Rhythm Pharmaceuticals

• Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023

  10/17/2023

  Rhythm Pharmaceuticals, Inc. announced several data presentations showing that setmelanotide therapy resulted in sustained and deepened weight loss in patients with severe obesity caused by rare MC4R pathway diseases during The Obesity Society’s Annual Meeting at ObesityWeek®.

• Rhythm Pharmaceuticals Announces New Employment Inducement Grants - October 13, 2023

  10/13/2023

  Rhythm Pharmaceuticals, Inc. announced that on October 10, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 18,295 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 12,530 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 5,765 shares of its common stock.

• Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®

  10/10/2023

  Rhythm Pharmaceuticals, Inc. today announced that six abstracts have been accepted for presentation – three oral presentations and three posters - at The Obesity Society’s Annual Meeting at ObesityWeek ® to be held in October.

• Rhythm Pharmaceuticals Presents New Data at ESPE 2023

  9/22/2023

  Rhythm Pharmaceuticals, Inc. today announced four oral presentations at the 61st Annual European Society for Paediatric Endocrinology (ESPE) Meeting being held September 21-23, 2023 in The Hague, Netherlands.

• Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

  9/19/2023

  Rhythm Pharmaceuticals, Inc. today announced that the European Medicines Agency (EMA) has issued a positive opinion on the Company’s orphan drug designation request for setmelanotide as a treatment for acquired hypothalamic obesity,

• Rhythm Pharmaceuticals Announces Update to September 2023 Conference Participation

  9/8/2023

  Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor pathway diseases, announced an update to its September conference calendar.

• Rhythm Pharmaceuticals Announces New Employment Inducement Grants - September 08, 2023

  9/8/2023

  Rhythm Pharmaceuticals, Inc. announced that on Sept. 5, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 25,455 shares of its common stock to six new employees, consisting of inducement stock options to purchase an aggregate of 16,970 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 8,485 shares of its common stock.

• Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

  9/6/2023

  Rhythm Pharmaceuticals, Inc. today announced that a new International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code for Bardet-Biedl Syndrome (BBS) was approved by the Centers for Disease Control and Prevention.

• Rhythm Pharmaceuticals to Present at Investor Conferences in September 2023

  8/28/2023

  Rhythm Pharmaceuticals, Inc. announced that Company management will present at three investor conferences in September:

• Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France

  8/7/2023

  Rhythm Pharmaceuticals, Inc. today announced that the French National Agency for Medicines and Health Products Safety (ANSM) and French National Authority for Health (HAS) have granted pre-marketing early access authorization AP1 (Autorisation d’Accès Précoce), for IMCIVREE® (setmelanotide), an MC4R agonist, for patients with lesional hypothalamic obesity.

• Rhythm Pharmaceuticals Announces New Employment Inducement Grants - August 04, 2023

  8/4/2023

  Rhythm Pharmaceuticals, Inc. announced that on August 2, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 39,720 shares of its common stock to eight new employees, consisting of inducement stock options to purchase an aggregate of 26,480 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 13,240 shares of its common stock.

• Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update

  8/1/2023

  Rhythm Pharmaceuticals, Inc. today reported financial results and provided a business update for the second quarter ended June 30, 2023.

• Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome

  7/19/2023

  Rhythm Pharmaceuticals, Inc. announced two new publications detailing the burden of hyperphagia and obesity for adult caregivers, families and patients living with Bardet-Biedl Syndrome based on results of The CAREgiver Burden in BBS study.

• Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023

  7/17/2023

  Rhythm Pharmaceuticals, Inc. announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 1, 2023 to report its second quarter 2023 financial results and provide a corporate update.

• Rhythm Pharmaceuticals Announces New Employment Inducement Grants - July 13, 2023

  7/13/2023

  Rhythm Pharmaceuticals, Inc. announced that on July 10, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 38,955 shares of its common stock to six new employees, consisting of inducement stock options to purchase an aggregate of 25,970 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 12,985 shares of its common stock.

• Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

  6/17/2023

  Rhythm Pharmaceuticals, Inc. announced data that showed meaningful weight loss was sustained and progressed in patients with hypothalamic obesity treated with setmelanotide for six months as part of the long-term extension of its Phase 2 trial.

• Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

  6/7/2023

  Rhythm Pharmaceuticals, Inc. today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 10:40 a.m. PT (1:40 p.m. ET).

• Rhythm Pharmaceuticals Announces New Employment Inducement Grants - June 06, 2023

  6/6/2023

  Rhythm Pharmaceuticals, Inc. announced that on June 2, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 33,450 shares of its common stock to seven new employees, consisting of inducement stock options to purchase an aggregate of 22,300 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 11,150 shares of its common stock.

• Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries

  5/22/2023

  Rhythm Pharmaceuticals, Inc. announced a collaboration with Genpharm Services FZ LLC to commercialize IMCIVREE® in Gulf Cooperation Council countries, including Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman and Bahrain.

• Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency

  5/8/2023

  Rhythm Pharmaceuticals, Inc. announced that Health Canada has approved IMCIVREE® for weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome or genetically-confirmed biallelic pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency due to variants interpreted as pathogenic, likely pathogenic, or of uncertain significance.